Canadian Pharmacy Compounding
Regulations Exam Practice Questions
And Correct Answers (Verified Answers)
Plus Rationale 2026 Q&A| Instant
Download Pdf
1. A licensed pharmacist practicing in a sterile compounding facility in
Ontario is asked to prepare a batch of parenteral nutrition solutions
for neonatal intensive care patients. During routine environmental
monitoring, the pharmacist discovers that the ISO Class 5 primary
engineering control exceeded acceptable microbial action limits the
previous evening. Which of the following actions is most consistent
with Canadian compounding standards and patient safety obligations?
A. Continue compounding because no visible contamination was identified
B. Release the compounded preparations after visual inspection only
C. Immediately quarantine affected preparations, investigate contamination
,sources, and suspend sterile compounding until corrective actions are
completed
D. Delegate responsibility for investigation entirely to the pharmacy
technician
C. Immediately quarantine affected preparations, investigate
contamination sources, and suspend sterile compounding until corrective
actions are completed
Environmental monitoring failures in sterile compounding environments
require immediate investigation because microbial contamination may
place patients at significant risk of infection or death. Canadian standards
modeled on NAPRA and USP principles require quarantine of potentially
affected products, root-cause analysis, and remediation before sterile
operations resume.
2. A pharmacist in Alberta compounds a non-sterile pediatric suspension
from commercially available tablets because no suitable pediatric
formulation exists in Canada. Which documentation element is legally
and professionally required in the compounding record?
A. The pharmacist’s favorite preparation method
B. The patient’s unrelated medical diagnoses
C. Lot numbers and expiry dates of all ingredients used
D. Marketing information regarding the manufacturer
,C. Lot numbers and expiry dates of all ingredients used
Compounding records must include traceability information for all
ingredients, including lot numbers and expiry dates. This documentation
supports recalls, quality assurance investigations, and patient safety
obligations required under Canadian pharmacy regulatory standards.
3. A pharmacy manager establishes a sterile compounding cleanroom
but fails to validate the airflow and pressure differentials before
commencing hazardous drug compounding. Which regulatory
principle is most directly violated?
A. Therapeutic duplication prevention
B. Environmental and engineering control validation requirements
C. Controlled substance destruction procedures
D. Prescription transfer authorization rules
B. Environmental and engineering control validation requirements
Sterile compounding facilities must undergo certification and validation to
ensure engineering controls function properly. Airflow integrity, pressure
differentials, and HEPA filtration performance are essential safeguards
against contamination and occupational exposure.
, 4. Under Canadian pharmacy compounding standards, which of the
following best describes the purpose of assigning beyond-use dates to
compounded sterile preparations?
A. To maximize pharmacy profitability
B. To replace manufacturer expiry dates indefinitely
C. To establish scientifically supported limits for safe use based on stability
and sterility risk
D. To eliminate the need for quality assurance testing
C. To establish scientifically supported limits for safe use based on stability
and sterility risk
Beyond-use dates are based on evidence related to sterility, chemical
stability, storage conditions, and contamination risk. They are intentionally
conservative because compounded products generally lack the extensive
stability testing conducted for commercially manufactured medications.
5. A pharmacist compounds a hazardous antineoplastic preparation
without using appropriate closed-system transfer devices or personal
protective equipment. Which consequence is most likely under
Canadian occupational and pharmacy regulations?
A. No regulatory concern exists if the patient receives the medication safely
B. Only the drug manufacturer is responsible for occupational exposure risks
C. The pharmacist and employer may face professional and workplace safety
Regulations Exam Practice Questions
And Correct Answers (Verified Answers)
Plus Rationale 2026 Q&A| Instant
Download Pdf
1. A licensed pharmacist practicing in a sterile compounding facility in
Ontario is asked to prepare a batch of parenteral nutrition solutions
for neonatal intensive care patients. During routine environmental
monitoring, the pharmacist discovers that the ISO Class 5 primary
engineering control exceeded acceptable microbial action limits the
previous evening. Which of the following actions is most consistent
with Canadian compounding standards and patient safety obligations?
A. Continue compounding because no visible contamination was identified
B. Release the compounded preparations after visual inspection only
C. Immediately quarantine affected preparations, investigate contamination
,sources, and suspend sterile compounding until corrective actions are
completed
D. Delegate responsibility for investigation entirely to the pharmacy
technician
C. Immediately quarantine affected preparations, investigate
contamination sources, and suspend sterile compounding until corrective
actions are completed
Environmental monitoring failures in sterile compounding environments
require immediate investigation because microbial contamination may
place patients at significant risk of infection or death. Canadian standards
modeled on NAPRA and USP principles require quarantine of potentially
affected products, root-cause analysis, and remediation before sterile
operations resume.
2. A pharmacist in Alberta compounds a non-sterile pediatric suspension
from commercially available tablets because no suitable pediatric
formulation exists in Canada. Which documentation element is legally
and professionally required in the compounding record?
A. The pharmacist’s favorite preparation method
B. The patient’s unrelated medical diagnoses
C. Lot numbers and expiry dates of all ingredients used
D. Marketing information regarding the manufacturer
,C. Lot numbers and expiry dates of all ingredients used
Compounding records must include traceability information for all
ingredients, including lot numbers and expiry dates. This documentation
supports recalls, quality assurance investigations, and patient safety
obligations required under Canadian pharmacy regulatory standards.
3. A pharmacy manager establishes a sterile compounding cleanroom
but fails to validate the airflow and pressure differentials before
commencing hazardous drug compounding. Which regulatory
principle is most directly violated?
A. Therapeutic duplication prevention
B. Environmental and engineering control validation requirements
C. Controlled substance destruction procedures
D. Prescription transfer authorization rules
B. Environmental and engineering control validation requirements
Sterile compounding facilities must undergo certification and validation to
ensure engineering controls function properly. Airflow integrity, pressure
differentials, and HEPA filtration performance are essential safeguards
against contamination and occupational exposure.
, 4. Under Canadian pharmacy compounding standards, which of the
following best describes the purpose of assigning beyond-use dates to
compounded sterile preparations?
A. To maximize pharmacy profitability
B. To replace manufacturer expiry dates indefinitely
C. To establish scientifically supported limits for safe use based on stability
and sterility risk
D. To eliminate the need for quality assurance testing
C. To establish scientifically supported limits for safe use based on stability
and sterility risk
Beyond-use dates are based on evidence related to sterility, chemical
stability, storage conditions, and contamination risk. They are intentionally
conservative because compounded products generally lack the extensive
stability testing conducted for commercially manufactured medications.
5. A pharmacist compounds a hazardous antineoplastic preparation
without using appropriate closed-system transfer devices or personal
protective equipment. Which consequence is most likely under
Canadian occupational and pharmacy regulations?
A. No regulatory concern exists if the patient receives the medication safely
B. Only the drug manufacturer is responsible for occupational exposure risks
C. The pharmacist and employer may face professional and workplace safety
